April 18, 2019 – For patients undergoing arthroscopic surgery to repair a torn rotator cuff, previous steroid injections into the shoulder don’t increase the risk of surgical-site infection – unless the injection is administered within one month before surgery, reports a study in the April 17, 2019 issue of The Journal of Bone & Joint Surgery. The journal is published in the Lippincott portfolio in partnership with Wolters Kluwer.
“Infection following arthroscopic rotator cuff repair occurred at a 65 percent to 75 percent greater rate when patients received a shoulder injection within one month of the surgical procedure,” according to the new research by Brian Forsythe, MD, of Rush University Medical Center, Chicago, and colleagues. But the study finds no increase in infection risk associated with steroid injections at any other time during the year before surgery.
Increased Infection Risk with Shoulder Injection One Month Before Surgery
The study included data on more than 60,000 patients who had arthroscopic surgery to repair a torn rotator cuff between 2007 to 2016, identified from a large insurer database. About 12,000 patients received a steroid injection in the year before surgery. The remaining 48,000 patients had no shoulder injection during that time. The overall infection rate was almost identical between groups: 0.7 percent for patients who had received a shoulder injection at any time in the year before surgery, and 0.8 percent in those who did not.
However, among patients who had a steroid injection one month or less before surgery, the infection rate was significantly higher than that in the control group: 1.3 percent. Injections received at any other interval during the year before rotator cuff repair – from two to 12 months – did not affect the postoperative infection risk.
After the authors adjusted for other factors, steroid injection in the month before surgery was the single strongest predictor of postoperative infection. Other risk factors identified were consistent with findings from previous studies: male sex, smoking, obesity, and diabetes.
Symptomatic rotator cuff tears are common, occurring in more than 30 percent of the population. Steroid injections can reduce pain and inflammation in patients with rotator cuff tears. If this and other “conservative” treatments (such as physical therapy) don’t provide enough improvement, rotator cuff surgery may be recommended.
Due to concern over the risk of infection, surgeons may delay rotator cuff repair in patients who have undergone shoulder injection. However, until now there was little evidence on the risks of infection after a preoperative injection.
The new findings suggest that infection risk is increased only for patients who have a steroid injection within one month before rotator cuff surgery. Thereafter, the timing of shoulder injections seems to have no effect on the risk of infection.
For orthopaedic surgeons, that’s an important piece of information, as many patients opt for – and insurers may require – a period of conservative treatment before surgery for rotator cuff tears. Dr. Forsythe and coauthors conclude, “If patients receive a corticosteroid injection to treat symptomatic rotator cuff tears, the results of this study suggest that physicians allow at least one month prior to proceeding with operative management to reduce postoperative infections.”
###
DOI: 10.2106/JBJS.18.00631
About The Journal of Bone & Joint Surgery
The Journal of Bone & Joint Surgery (JBJS) has been the most valued source of information for orthopaedic surgeons and researchers for over 125 years and is the gold standard in peer-reviewed scientific information in the field. A core journal and essential reading for general as well as specialist orthopaedic surgeons worldwide, The Journal publishes evidence-based research to enhance the quality of care for orthopaedic patients. Standards of excellence and high quality are maintained in everything we do, from the science of the content published to the customer service we provide. JBJS is an independent, non-profit journal.
About Wolters Kluwer
Wolters Kluwer is a global leader in professional information, software solutions, and services for the health, tax & accounting, finance, risk & compliance, and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer, headquartered in the Netherlands, reported 2017 annual revenues of €4.4 billion. The company serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,000 people worldwide.
Wolters Kluwer Health is a leading global provider of trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students with advanced clinical decision support, learning and research and clinical intelligence. For more information about our solutions, visit //healthclarity.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.
